

Special Report | Research

21 February 2020

#virus

China

COVID-19: Activity tracking- watch for a turning point

Notwithstanding all the caveats on Chinese statistics and unknowns regarding the virus, the broad declining trend seen in China's new cases outside Hubei suggests the government's unprecedented control measures are paying off. The cost of the containment, as expected, is huge. February activity has been in deep contraction, by all measures. In this report, we try to gauge the extent of disruptions and the recovery timeline, as well as when a turning point may arise and risks areas. We try to derive a rough aggregate path for activity on a weekly basis, after cross-checking daily-weekly survey/big data, including operation rates, migration index, and self-reported ratios of resumption from local governments and industrial associations.

Overall, our weekly guesstimates suggest that actual manufacturing activity (Figure 1) likely contracted by 55-60% y/y in the first three weeks of February, due to low operation rates. This brings actual growth in February closer to our heavy (risk 2) disruption scenario than the medium (base case) disruption scenario, as we have outlined in previous reports on *1 February* and *7 February*. The NBS manufacturing PMI is on track to fall below 40 in February, by our estimates, assuming the survey is to be completed by around the 25th of the month.

That said, we see earlier signs of a bottoming in the manufacturing activity contraction, with operation rates picking up pace this past week, especially in more market-oriented and economically important provinces, such as Guangdong and Zhejiang. Barring a reescalation of the outbreak, we expect more activity indicators to show a pickup in coming weeks. We note that some weekly hard data, such as home sales and to a lesser extent coal consumption, as well coke plant operating rates, have started to recover, albeit still pointing to very weak activity (Figures 8 and 9).

Our base case forecast expects an easing outbreak to lead to an accelerated pace of workers and plants returning to operations by end-February, with operation rates improving to 90-100% in the coming weeks. The week of 24 February remains key to assess the risks.

Such optimism is in part suggested by the Chinese government's commitment to "maintaining the economic social development target and winning the battle against the epidemic" - the "两手抓" strategy highlighted in Politburo meetings since early February (3 Feb, 9 Feb). Many local governments appear to have stepped up directives to accelerate and facilitate the resumption of production while containing the outbreak in the past week. Moreover, despite the shock, we note that some local governments, eg. Zhejiang and Jiangsu provinces, have recently, on 17 February, highlighted that they will keep their pre-COVID-19 2020 growth targets unchanged (Zhejiang: 6-6.5% from 6.5% in 2019; Jiangsu: 6-6.5% from 6-6.5% in 2019). In view of these, we expect China to still set its 2020 growth target at 6-6.5% or possibly 6-6%, compared with 6-6.5% in 2019.

This is a Special Report that is not an equity or a debt research report under U.S. FINRA Rules 2241-2242.

PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES STARTING AFTER PAGE 8

Jian Chang* +852 2903 2654 jian.chang@barclays.com Barclays Bank, Hong Kong

Yingke Zhou* +852 2903 2653 yingke.zhou@barclays.com Barclays Bank, Hong Kong

Eric Zhu*
+852 2903 2655
eric.zhu@barclays.com
Barclays Bank, Hong Kong

www.barclays.com

^{*} This author is a debt research analyst in the Fixed Income, Currencies and Commodities Research department and is neither an equity research analyst nor subject to all of the independence and disclosure standards applicable to analysts who produce debt research reports under U.S. FINRA Rule 2242.


We are mindful of the risks to such constructive views. Key risk areas to watch include:

- 1. (Longer disruption) COVID-19 outbreak re-escalates (see more details in the section on the disease development): this is the most important factor that could determine how fast economic activities can return to normal.
- 2. **(Longer/greater disruption)** Local governments continue to enforce strong containment measures as a precaution against re-escalation of the outbreak, including:
 - home quarantine (requested for all workers or from highly infected regions)
 - denying approval for factory/business resumption
 - restricting inter-province/city transportation
 - local community lockdown.
- 3. (Longer/greater disruption) Practical constraints that deter quick resumption of work:
 - slow recovery in logistics/transportation;
 - slow recovery in upstream supply chains (eg. mining and smelting, steel);
 - lack of sufficient containment equipment during work (eg. mask supply).

Activity tracks more closely to heavy disruption scenario

Our weekly guesstimates suggest that actual manufacturing activity likely contracted by 55-60% y/y in the first three weeks of February, reflecting low operation rates under the strict containment measures as well as practical constraints. This suggests downside risks to our 1Q GDP growth forecasts. That said, our base case expects some accelerated pace of pickup in the operation rates as well as activities in the coming weeks to make up the loss, based on our assessment of the COVID-19 outlook and local government behaviours.

FIGURE 1
Recovery timeline: mapping operation rates with manufacturing activities



Note: *Manufacturing activities refer to the production output in manufacturing industries (secondary sector with the exclusion of construction and mining industries), which in total accounted for ~30% of China's GDP. ** Group 1: Hubei province (4.6% of China GDP). Group 2: 23 provinces (largely covering central and eastern China, 87% of China GDP). Group 3: the remaining 7 provinces (8% of China GDP). See *China: Coronavirus: GDP forecast downgrade*, 7 February 2020 Source: Barclays Research

21 February 2020

New confirmed: China 6,000 Hubei province - Wuhan city 5,000 China ex. Hubei New suspected: China (RHS) 6,000 Hubei province (RHS) 4,000 5.000 China ex. Hubei (RHS) 4,000 3,000 3,000 2,000 1614 2,000 1279 1.000 889 1,000 2-Feb 21-Jan 23-Jan 25-Jan 27-Jan 29-Jan 31-Jan 4-Feb 6-Feb 8-Feb 10-Feb 12-Feb 14-Feb 16-Feb 18-Feb 20-Feb 22-Feb 24-Feb S-Dar End Feb Wuhan reports Travel ban LNY WHO declares New confirmed New suspected Hubei changes Base case** for Watch for risk near Base case** for first confirmed in Wuhan diagnosis global health outside Hubei outside Hubei end of 2-wk home outside Hubei Hubei being methodology peaks peaks emergency quarantine for first being contained contained (near-zero new (near-zero new round of return cases) workers cases)

FIGURE 2
COVID-19 outbreak: being contained outside Hubei by end-Feb appears on track

Source: PRC and Hubei NHC, Wind, Barclays Research

Disease developments: Base case assumptions still on track

We think the broadly declining trends in new confirmed (excluding jail cases) and suspected cases support our constructive view that COVID-19 will be contained outside Hubei by end-February (and in Hubei by April). This anchors the assumption of "length of disruption" in our base case forecasts.

Notwithstanding all the caveats on Chinese statistics and the now twice change of methodology (in Hubei), data show that China's new confirmed and suspected cases (outside Hubei) peaked on 3 February and 6 February (Figure 2), respectively, before a sudden rise in new confirmed cases on 20 February. We note this latest jump to 258 largely came from two prisons in the Shandong (200 cases) and Zhejiang (27 cases) provinces, likely reflecting a statistical revision to include previously un-reported jail cases. Excluding the two prison outbreaks, new confirmed cases were still broadly on a declining trend, down to 31 on 20 February from 45 on 19 February.

Inside the epicentre, Hubei province's new confirmed cases peaked on 4 February, before a sudden eightfold surge on 12 February following a methodology change. The new confirmed cases in Hubei visibly declined after 12 February, before the rise on 20 February (in part due to inclusion of prison cases as well). Meanwhile, the suspected cases in Hubei have generally declined since the peak on 9 February, but have shown new signs of pick-up since 19 February, following the intensified city-wide community screening undertaken by the new provincial leadership.

We have in earlier reports (*1 Feb* and *7 Feb*) highlighted 6-8 February and end-February as two windows to watch for turning points. Assuming containment measures are effective, two peaks are expected before these two windows, in view of the lockdown of Wuhan city (from 23 January) and the official return to work in most parts of the country (from 10 February). So the latest jump arguably still falls within our expectations.

^{*258} new cases ex.Hubei on 20 Feb included 227 from two prisons in Shandong and Zhejiang.

^{**}See China: Coronavirus: GDP forecast downgrade, 7 February 2020

We are mindful of the risks and unknowns of the virus, with 24 February still a critical date to watch

Risk of the outbreak lasting longer or re-escalate remains, due to uncertainties related to:

- 1. more workers traveling back to work sites and resuming production and home confinement being relaxed;
- 2. further changes in statistical/diagnosis methodology (and incomplete data disclosure) adding to difficulties in making consistent assessment of the outbreak development;
- 3. new source of outbreak (eg, prisons reported on 20 February), with hospitals and factories among the most vulnerable places (eg. Beijing Fuxing hospital reported 34 confirmed cases on 19 February, and a factory under Panzhihua Iron and Steel in Chongqing reported 2 confirmed cases on 10 February, with another 131 in close contact being observed); and
- 4. unknown variation in the virus that may lead to increased contagiousness (eg. new type of transmission).

We think the week of 24 February remains critical to assess the risks, especially as it marks the first round of workers returning from their two-week (home) containment. Should there be significant and consecutive increases in new confirmed cases by the end of the week, this could trigger another round of stricter/longer containment measures to force a pause in the ongoing work recovery. Hence a longer "length of disruption" than under our baseline, adding to downside risks to our growth outlook.

Tracking the contraction and recovery path by guesstimating the aggregate operation rates

Investor concerns have turned away from a weak Q1 to when activity will pick up. We discuss our use of provincial-specific operation rate/migration data to guesstimate the extent of disruption/potential recovery. This helps us to paint a macro picture, derive a guesstimate for an aggregate activity path (Figure 1), as well as allow us to cross-check with other sectoral weekly activity data.

FIGURE 3
Tracking operating rates and implied y/y growth across our three groups

	Operation rates (actual vs 2 scenarios) and migration data					Implied y/y growth (actual vs 2 scenarios)		
Groups	Return to work (official annoucment)	Operation rates (offical report: week 10 Feb, 17 Feb)	Operation rates (medium disruption assumption: week 10 Feb,	Operation rates (heavy disruption assumption: week 10 Feb,	Inbound migration as % of last year (actual: week 10 Feb, 17	Implied y/y growth (week 10 Feb, 17 Feb)	Implied y/y growth (medium disruption assumption: week 10 Feb, 17 Feb)	Implied y/y growth (heavy disruption assumption: week 10 Feb, 17 Feb)
Group 1 (~5% of GDP)	11-Mar	20%*	20%, 30%	10%,10%		-80%	-80%, -70%	-90%, -90%
Group 2 (~87% of GDP)	10-Feb	~40%, ~45%*	70%, 80%	30%, 40%	~10%, ~20%	-60% , -55%, in between medium and heavy disruption)	-30%, -20%	-70%, -60%
Guangdong, Jiangsu, Shandong, Zhejiang (~35% of GDP)	10-Feb							
Guangdong (10.9%)	10-Feb	60%			~30%, ~35%	-40%		
Jiangsu (10.1%)	10-Feb	65%			~24%, ~27%	-35%		
Shandong (7.2%)	10-Feb	70%			~25%, ~29%	-30%		
Zhejiang (6.3%)	10-Feb	33%, ~60%			~14%, ~19%	-67% (17 Feb: ~-40%)		
Group 3 (~8% of GDP)	03-Feb	~85%, ~90%*	80%, 90%	40%, 50%		-15%	-20%, -10%	-60%, -50%

^{*}Note: operation rate is defined by the share of factories returning to normal production. Sources: Haver, Wind, Barclays Research

Operation rate saw a pickup in the past week, especially in more market-oriented provinces. Following the official production resumption on 10 February, we track the operation rates in China's four economically most important provinces, which together account for 35% of national GDP.

We estimate a pickup in the operation rates over the past week (week of 17 February). According to local government reports, the operation rates in Guangdong, Jiangsu, Shangdong and Zhejiang were 60%, 65%, 70% and 33%, respectively, in the week of 10 February. While these ratios look higher than what's suggested by the on-the-ground information, we think the trend is for a visible improvement in these provinces. Using data for industrial enterprises above designated size (with annual income over CNY20mn), we estimate operation rates in Zhejiang provinces could have doubled from a week ago.

This reflects local government and private businesses' efforts to resume production. For example, Zhejiang province offer chartered transport, rewards to get rural migrants back to work. As of 19 February, at least 21,800 workers from provinces with labour surpluses, including Guizhou, Sichuan and Anhui, have been brought in by chartered railways, planes, and buses (*SCMP*, Coronavirus: China's east coast provinces offer chartered transport to get rural migrants back to work, 19 Feb 2020). Cities in GuangDong provinces started this even earlier, with Dongguan (ranking #1 in inbound travel in the week ending 14 February) using chartered buses to bring back migrant workers from Chongqing and Yunan etc.


Variations across sectors: we note that the operation rate in labour intensive sectors (represented by textile and rubber: <30% as of week of 10 February) was hit hard compared with high-tech sectors (represented by semiconductor and medical: 60-80%).

Migration data: We also try to gauge the resumption in work by tracking the daily level of travel returning to some areas that rely heavily on migrant workers. If using the 2019 travel during the first three weeks after LNY as a benchmark, we note Guangdong's inbound travel (best among the four) has reached 29% of last year's level, while Zhejiang's progress is the slowest, only recovering to 14% thus far. Overall, as of 20 February, we estimate the inbound migration as a % of last year, was around 20% in Guang Dong, ZheJiang, ShanDong, and Jiangsu.

When will we see the turning point?


Overall, the two indicators above confirm what is widely known, most high-frequency indicators as of the week ending 14 February, including metals and mining, auto sales and hotel revenue, as well as transportation/travel data (Figure 4-7), all suggest very subdued activities on the ground, hence a large y/y contraction for February.

FIGURE 4
Mining and smelting: steel plant operating rate



Source: Wind, Barclays Research

FIGURE 5
Mining and smelting: coke plant operating rate



Source: Wind, Barclays Research

FIGURE 6

Passenger car sales





FIGURE 7

Hotel revenue per room



Source: Wind, Barclays Research

That said, we see early signs of bottoming in some indicators. Specifically, some weekly activity data (including coal consumption by six major power plants, and home sales in tier 1 cities, as well as coke plant operating rates, Figure 5, Figure 8 and 9) started to bottom out around 20 February, albeit still at very weak levels, and evaluated cumulatively.

Meanwhile, gauging from the migration data, we think the population returning to work (as suggested by the Baidu Migration index) has also likely bottomed this week, albeit still low relative to last year. The Baidu index shows a visible pickup in inbound population starting from 17 February into Zhejiang. This suggests activities in the coming weeks could pick up at an accelerated pace, with operation rates reaching 90-100% or weekend/more shifts to make up for the losses, as required for our base forecasts to hold, provided no new outbreaks.

Source: : Wind, Barclays Research

FIGURE 8

The week ending 21 Feb saw some rebound in home sales...





FIGURE 9

...and coal consumption by six major power plants



Source: : Wind, Barclays Research

Looking ahead, provided there are no new outbreaks or resurging cases outside Hubei, we think it is possible that more activity indicators could show a pickup in the week of 24 February and in March due to: 1) the end of the 14-day quarantine for early returnees; and 2) more provinces in Group 2 of our model gradually easing the restriction on travel and supporting factories to resume production, in addition to provinces that are more market-oriented and have stronger governance capacity, such as Guangdong and Zhejiang.

That said, the NBS manufacturing PMI is on track to fall below 40 in February, by our estimates, assuming the survey is completed by the 25th of the month, as is typically the case, compared with 50 in January and 49.2 a year ago.

Local governments production and containment capacity and policies, key areas to watch

The huge gap in handling the COVID-19 outbreak across different provinces and cities in China suggests great variations in governance capacity, economic strength, and local leaders' philosophy, in our view. Local government capacity to execute the central government's 两手抓 strategy will be key to watch for the growth outlook.

- Central government's 两手抓 strategy with an emphasis on returning to work since mid-Feb. In a Xinhua article released on 9 February, the day before the nation's officials were due to return to work, the central government emphasised the need to meet this year's economic targets, while fighting the virus. The article serves as a reiteration of President Xi's thinking following the Politburo meeting on 3 February (see "Xi chairs leadership meeting on epidemic control", Xinhua). In the State Council meeting on 11 February, Premier Li stressed the importance of resuming work and production while the fight against COVID-19 continues. While Hubei's top priority remains epidemic control, he urged other areas (especially less infected parts) to push forward with getting back to work in an orderly manner.
- Local governments' incentives/restrictions to resumption of work. We note some economically important provinces vowed to achieve a reasonable growth target in 2020 (see below). Against this backdrop, many east coast provinces have stepped up efforts to resume production since mid-February. For example, Zhejiang and Guangzhou provinces offer chartered transport, as well as rewards to get rural migrants back to work. However, there are also some impairments to the resumption of work for some

FIGURE 10 GDP manufacturing and services





FIGURE 11

NBS manufacturing PMI to fall sharply in Q1 before recovering in Q2



- inland provinces, largely due to transport restrictions and lockdowns that have hampered the flow of migrant workers, and some programmes of enforced quarantine for returning workers.
- Local government 2020 growth targets: In Zhejiang province, where more factories were affected in the first half of February, the local government on the 17th confirmed the growth target of 6-6.5% in 2020, slightly lower than the target of 6.5% in 2019. This means the government will roll out more measures to stimulate growth. Meanwhile, Jiangsu province on the same day, also posted its growth target of 6.0%, versus 6-6.5% in 2019.
- Local government relaxation of housing policies. A number of local governments (eg. Shenzhen, Suzhou, Wuxi, Nanchang) have also announced some easing of housing policies. We think such easing measures for property markets in some regions will lend some support to property investment and sales, albeit with a lag (any effect is likely be to be seen from March onwards).

Analyst Certification

We, Jian Chang, Yingke Zhou and Eric Zhu, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures:

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise. In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://publicresearch.barcap.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://publicresearch.barcap.com/S/CM.htm.

All pricing information is indicative only. Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

Disclaimer:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors and not for retail investors. It has been distributed by one

or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as "institutional debt research reports" unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area ("EEA"): This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A. This material is distributed in the Cayman Islands and in the Bahamas by Barclays Capital Inc., which it is not licensed or registered to conduct and does not conduct business in, from or within those jurisdictions and has not filed this material with any regulatory body in those jurisdictions.

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143

Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585;

Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank. This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC. None of Barclays Bank PLC, nor any other Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001. This material is distributed in New Zealand by Barclays Bank PLC, but it has not been registered, filed or approved by any New Zealand regulatory authority or under or in accordance with the Financial Markets Conduct Act of 2013, and this material is not a disclosure document under New Zealand law.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). This material does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any securities or investment products in the UAE (including the Dubai International Financial Centre) and accordingly should not be construed as such. Furthermore, this information is being made available on the basis that the recipient acknowledges and understands that the entities and securities to which it may relate have not been approved, licensed by or registered with the UAE Central Bank, the Dubai Financial Services Authority or any other relevant licensing authority or governmental agency in the UAE. The content of this report has not been approved by or filed with the UAE Central Bank or Dubai Financial Services Authority. Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2020). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.